Market Size of Enzyme-Linked Immunosorbent Assay Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
CAGR | 8.00 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Enzyme-Linked Immunosorbent Assay Market Analysis
The enzyme-linked immunosorbent assay (ELISA) market is projected to register a CAGR of 8% during the forecast period.
COVID-19 has increased the demand for immunoassays like ELISA across the globe. This is mainly due to the increase in infection rates, which increased the necessity for effective diagnosis. According to the data published in the NCBI Journal in March 2020 titled "Diagnosing COVID-19: The Disease and Tools for Detection", SARS-CoV-2 can be detected by the ELISA with high accuracy. Moreover, in February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit to detect immunoglobulin G (IgG) antibodies qualitatively to SARS-CoV-2 in human serum or plasma. Thus, the increasing demand for cost-effective diagnoses to get the appropriate treatment is expected to drive the market's growth.
The increasing incidence of infectious diseases such as HIV, dengue, hepatitis, malaria, influenza, and various other infections is a significant factor contributing to the market's growth. According to the WHO data updated in July 2022, an estimated 37.7 million people were living with HIV globally at the end of 2020, and over two-thirds (25.6 million) of them are in the African region. Also, the same source stated that dengue fever is one of the top ten global health threats. There has been a 30-fold increase in global dengue incidence over the past 50 years. According to World Health Organization updates from June 2022, over 354 million people across the globe live with Hepatitis B or C infections. Such an increasing incidence of infectious diseases increased the demand for diagnosis. The increased usage of advanced diagnostic tools, such as enzyme-linked immunosorbent assays for screening diseases, is attributed to the market's growth.
Furthermore, the increase in the geriatric population at risk of developing various infections and chronic disorders also plays a crucial role in driving the market's growth. as per the data updated by NCBI in July 2021, potentially serious infections are quite common in older patients than in younger ones. Such factors are expected to significantly increase the demand for the enzyme-linked immunosorbent assay market, thereby increasing the market's growth.
Moreover, key market players' innovations in enzyme immunoassays also add to the market growth. For instance, in September 2021, Bio-Rad launched the Bio-PlexPro Human IgA and IgM SARS-CoV-2 panels to detect IgA and IgM antibodies against four SARS-CoV-2 antigens. The multiplex immunoassay panels helped the vaccine developers determine therapeutic efficacy from development through clinical phases and postmarket surveillance studies. Also, in December 2021, ArcticZymes Technologies launched a new ELISA immunoassay product, an essential support product for consumers which used the M-SAN HQ enzyme in biomanufacturing processes for gene therapy and viral vaccine production. Such product launches are boosting market growth.
However, stringent regulations for approval and a lack of skilled personnel handling equipment are restraining the market's growth.